Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Sandoz's Exelon shows positive results in phase III

Aug. 9, 1996

NMDA antagonists claimed by E. Merck

Aug. 9, 1996

Dainippon's new compound superior to metoclopramide for digestive function improvement

Aug. 9, 1996

Teva's Copaxone progresses toward FDA approval

Aug. 9, 1996

5-HT1A agonist with alpha1-adrenoceptor-blocking properties from Byk Gulden

Aug. 9, 1996

Multiuse melatonergic 3-alkoxybenzylpiperidine derivatives from Bristol-Myers Squibb

Aug. 9, 1996

ADIR describes compunds with high affinity for 5-HT2C and/or 5-HT3C receptors

Aug. 9, 1996

Lidocaine nasal drops shown effective for fast migraine pain relief

Aug. 9, 1996

5-HT1 agonists described by Merck & Co.

Aug. 9, 1996

Actiq to undergo phase III clinical trials

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...